Harnessing serotonergic and dopaminergic pathways for lymphoma therapy: evidence and aspirations.
Growing evidence supports the notion that pharmaceutical targeting of the 5-hydroxytryptamine (5-HT) and dopamine (DA) systems offers the potential to treat human immune system disorders. This review describes this emerging area of research, which has the benefit of being supported by a relatively detailed understanding of these monoamine systems within other tissues of the body. Furthermore, the availability of a number of pharmaceutical agents originally developed to manipulate central monoamine function, offer many suitable drug candidates to test their therapeutic potential in the immune pathology arena.
Barnes
Nicholas M
NM
Division of Neuroscience, The Medical School, Vincent Drive, Birmingham B15 2TT, United Kingdom. n.m.barnes@bham.ac.uk
Gordon
John
J
D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism; D004298:Dopamine / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007107:Immune System / Q000276:immunology; D008223:Lymphoma / Q000276:immunology / Q000378:metabolism* / Q000628:therapy*; D012701:Serotonin / Q000276:immunology / Q000378:metabolism*; D015398:Signal Transduction / Q000276:immunology
D015306:Biogenic Monoamines; D012701:Serotonin; D004298:Dopamine